Lilly raised sales guidance for third time this year as Zepbound sales soar. Its stock is rallying.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S.
The drugmaker continues to dominate the market for prescription weight-loss drugs in the U.S. This story matters for Finance & Markets readers tracking trade. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. Trade-News.com curates and briefs the finance & markets stories that matter. Our editorial policy →
Get the daily trade signal